Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

  • ID: 4745168
  • Report
  • Region: Global
  • 180 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AbbVie
  • Astellas
  • Bristol-Myers Squibb
  • Corbus Pharmaceuticals
  • Gilead Sciences
  • Johnson & Johnson
  • MORE

Summary
Rheumatic disorders are a wide range of conditions which are characterized by chronic pain, with some of the most common conditions being osteoarthritis (OA) and rheumatoid arthritis (RA), and it is estimated that about one in four adults in America are diagnosed with a rheumatic disorder. The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

The rheumatic disorders market is expected to see good growth over the forecast period, increasing from $58.97 billion in 2017 at a compound annual growth rate (CAGR) of 4.46%. The US market accounted for approximately 43% of the global market in the baseline year 2017, and this is projected to remain stable over the forecast period.

The incidence of many indications within the rheumatic disorders therapy area continues to rise and as the global population ages prevalence will increase which is a key driver of market growth. By way of example, the total population living with OA across the seven major markets is expected to increase from 125.76 million in 2017 to 138.44 million in 2024. Market growth will also be driven by the entry of new products to the market, with two drug classes in particular driving strong market growth.

The rheumatic disorders market is dominated by a number of blockbuster drugs, which target tumor necrosis alpha (TNF-a), a key pro-inflammatory cytokine. However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced market dominance.

The therapy market is dominated by top pharmaceutical companies with 18 of the top 20 pharma companies having at least one marketed or pipeline rheumatic disorders product. By 2024, the 10 companies generating the most revenue in the rheumatic disorders therapy area are all top 20 pharmaceutical companies.

The report "Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry" covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

Forecast projections to 2024 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major drug classes are provided within the report.

Scope

  • How is the rheumatic disorders landscape expected to change?
  • Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
  • Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
  • Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
  • The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
  • What types of companies are involved in the rheumatic disorder therapy area?
  • Will the current market leaders retain their dominance over the forecast period?
  • How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to buy
This report will allow you to:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
  • Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the rheumatic disorder drug market
  • Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
  • Identify which two drug classes will see particularly strong market growth over the forecast period
  • See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
  • Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Astellas
  • Bristol-Myers Squibb
  • Corbus Pharmaceuticals
  • Gilead Sciences
  • Johnson & Johnson
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Overview
2.1.1 Rheumatoid Arthritis
2.1.2 Osteoarthritis
2.1.3 Osteoporosis
2.1.4 Systemic Lupus Erythematosus
2.1.5 Psoriatic Arthritis
2.2 Etiology
2.3 Pathophysiology
2.3.1 Rheumatoid Arthritis
2.3.2 Osteoarthritis
2.3.3 Osteoporosis
2.3.4 Systemic Lupus Erythematosus
2.3.5 Psoriatic Arthritis
2.4 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.4.1 Rheumatoid Arthritis
2.4.2 Osteoarthritis
2.4.3 Osteoporosis
2.4.4 Systemic Lupus Erythematosus
2.4.5 Psoriatic arthritis
2.5 Treatment
2.5.1 Rheumatoid Arthritis
2.5.2 Osteoarthritis
2.5.3 Osteoporosis
2.5.4 Systemic Lupus Erythematosus
2.5.5 Psoriatic Arthritis

3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab) - AbbVie
3.3 Enbrel (etanercept) - Amgen
3.4 Simponi (golimumab) - Johnson & Johnson
3.5 Remicade (infliximab) - Johnson & Johnson
3.6 Rituxan (rituximab) - Roche
3.7 Stelara (ustekinumab) - Johnson & Johnson
3.8 Cosentyx (secukinumab) - Novartis
3.9 Prolia (denosumab) - Amgen
3.10 Orencia (abatacept) - Bristol-Myers Squibb
3.11 Actemra (tocilizumab) - Roche
3.12 Benlysta (belimumab) - GlaxoSmithKline
3.13 Forteo (teriparatide) - Eli Lilly

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecule Types in the Pipeline
4.4 Molecular Targets in the Pipeline
4.5 Clinical Trials Landscape
4.5.1 Clinical Trial Failure Rates
4.5.2 Clinical Trial Duration
4.5.3 Clinical Trial Size
4.5.4 Cumulative Clinical Program Size
4.6 Assessment of Key Pipeline Products
4.6.1 Upadacitinib tartrate - AbbVie
4.6.2 Filgotinib - Gilead Sciences
4.6.3 Lenabasum - Corbus Pharmaceuticals
4.6.4 Evenity (romosozumab) - Amgen / UCB / Astellas
4.6.5 Avacopan - ChemoCentryx
4.6.6 Pegadricase - Selecta Biosciences
4.6.7 Anifrolumab - AstraZeneca

5 Multi-scenario Market Forecast to 2024
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Products Acting on Tumor Necrosis Factor-Alpha
5.3.2 Products Acting on Interleukins and Interleukin Receptors
5.3.3 Products Acting on Protein Kinases
5.3.4 Products Acting on Cell Surface Antigens
5.3.5 Products Acting on Hormones and Hormone Receptors

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 AbbVie
6.1.2 Amgen
6.1.3 Johnson & Johnson
6.1.4 Novartis
6.1.5 Pfizer
6.1.6 Roche
6.1.7 Eli Lilly
6.1.8 Bristol-Myers Squibb
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Indication and Value
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication and Value
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 Co-development Deals with Disclosed Values

8 Appendix
8.1 References
8.2 Figures of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer

List of Tables
Table 1: Rheumatic Disorders Drugs Market, Global, Etiology of RA, OA, Osteoporosis, SLE and PsA, 2018
Table 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology of Key Rheumatic Disorders Indications, 2018
Table 3: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within RA, 2018
Table 4: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for RA, 2018
Table 5: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within OA, 2018
Table 6: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for OA, 2018
Table 7: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within Osteoporosis, 2018
Table 8: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for Osteoporosis, 2018
Table 9: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within SLE, 2018
Table 10: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for SLE, 2018
Table 11: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within PsA, 2018
Table 12: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for PsA, 2018
Table 13:Rheumatic Disorders Drugs Market, Global, Key Marketed Products Overview, 2018
Table 14: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Humira, 2018
Table 15: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Enbrel, 2018
Table 16: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Simponi, 2018
Table 17: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Remicade, 2018
Table 18: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Rituxan, 2018
Table 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Stelara, 2018
Table 20: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Cosentyx, 2018
Table 21: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Prolia, 2018
Table 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Orencia, 2018
Table 23: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Actemra, 2018
Table 24: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Benlysta, 2018
Table 25: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Forteo, 2018
Table 26: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024
Table 27: Rheumatic Disorders Drugs Market, Global, Use of Generics Across Key Indications, 2018
Table 28: Rheumatic Disorders Drugs Market, Global, Forecast Revenue by Company (%), 2017-2024

List of Figures
Figure 1: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2017-2024
Figure 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoarthritis, 2017-2024
Figure 3: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoporosis, 2017-2022
Figure 4: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Systemic Lupus Erythematosus, 2017-2024
Figure 5: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Psoriatic Arthritis, 2017-2024
Figure 6: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Humira ($bn), 2006-2024
Figure 7: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2024
Figure 8: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2024
Figure 9: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2024
Figure 10: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024
Figure 11: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010-2024
Figure 12: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2024
Figure 13: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Prolia ($bn), 2010-2024
Figure 14: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Orencia ($bn), 2014-2023
Figure 15: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Actemra ($bn), 2016-2024
Figure 16: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Benlysta ($m), 2011-2024
Figure 17: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Forteo ($bn), 2006-2024
Figure 18: Rheumatic Disorders Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Stage of Development, Molecule Type and Program Type, 2018
Figure 20: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Stage of Development, 2018
Figure 21: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecule Type, 2018
Figure 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Molecular Target, 2018
Figure 23: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecular Target, 2018
Figure 24: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Attrition Rate by Stage of Development (%), 2006-2018
Figure 25: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2018
Figure 26: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2018
Figure 27: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2018
Figure 28: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018
Figure 29: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2018
Figure 30: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2018
Figure 31: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2018
Figure 32: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018
Figure 33: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2018
Figure 34: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006-2018
Figure 35: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2018
Figure 36: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018
Figure 37: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2018
Figure 38: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2018
Figure 39: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2018
Figure 40: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Upadacitinib tartrate ($bn), 2019-2024
Figure 41: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Filgotinib ($bn), 2019-2024
Figure 42: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Lenabasum ($bn), 2021-2024
Figure 43: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Evenity (romosozumab) ($m), 2019-2024
Figure 44: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Avacopan ($m), 2021-2024
Figure 45: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Pegadricase ($m), 2020-2024
Figure 46: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Anifrolumab ($m), 2019-2024
Figure 47: Rheumatic Disorders Drugs Market, Global, Market Size ($bn), 2017-2024
Figure 48: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024
Figure 49: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-a ($bn), 2017-2024
Figure 50: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins and Interleukin Receptors ($bn), 2017-2024
Figure 51: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Protein Kinases ($bn), 2017-2024
Figure 52: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Targeting Cell Surface Antigens ($bn), 2017-2024
Figure 53: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Hormone Receptors ($bn), 2017-2024
Figure 54: Rheumatic Disorders Drugs Market, Global, Company Analysis Matrix, 2017-2024
Figure 55: Rheumatic Disorders Drugs Market, Global, Cluster by Growth and Market Share, 2017-2024
Figure 56: Rheumatic Disorders Drugs Market, Global, Forecast Market Share by Company (%), 2017-2024
Figure 57: Rheumatic Disorders Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024
Figure 58: Rheumatic Disorders Market, Global, Revenues by Route of Acquisition, 2017-2024
Figure 59: Rheumatic Disorders Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017-2024
Figure 60: Rheumatic Disorders Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017-2024

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • ChemoCentryx
  • Corbus Pharmaceuticals
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Roche
  • Selecta Biosciences
  • UCB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll